Oruka Therapeutics, Inc.
ORKA
Market Cap$34.82M
Close$
$3.61
71.3% downside
Current Fair Value
71.3% downsideOvervalued by 71.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $34.82 Million |
|---|---|
| Enterprise Value | $-44,262,816.00 |
| Dividend Yield | $- (-%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.74 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | -0.1 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Oruka Therapeutics, Inc.
28 employees
CEO: Dr. Lawrence Otto Klein Ph.D. Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.